First Clinical Study on Long-Acting Growth Hormone Therapy in
                    Children with Turner Sydrome

Xinying Gao; Jiajia Chen; Bingyan Cao; Xinyu Dou; Yaguang Peng; Chang Su; Miao Qin; Liya Wei; Lijun Fan; Beibei Zhang; Chunxiu Gong

doi:10.1055/a-1842-0724

Hormone and Metabolic Research, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Horm Metab Res 2022; 54(06): 389-395
DOI: 10.1055/a-1842-0724

Original Article: Endocrine Care

First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome

Xinying Gao^‡

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

²Department of pediatrics, Beijing Liangxiang Hospital, Beijing, China

,

Jiajia Chen^‡

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Bingyan Cao

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Xinyu Dou

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Yaguang Peng

³Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Chang Su

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Miao Qin

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Liya Wei

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Lijun Fan

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Beibei Zhang

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

,

Chunxiu Gong

¹Department of Endocrinology, Genetics and Metabolism, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

› Institutsangaben

Abstract

Study on long-acting growth hormone (LAGH) therapy in Turner syndrome (TS) is a 2-year retrospective study including patients diagnosed with TS from 2018–2021. Patients were divided into four groups: Group 1 to 4 were low dose (0.1 mg/kg/ w), high-dose (0.2 mg/kg/w) LAGH, daily GH (0.38 mg/kg/w), and untreated control. The efficacy and safety data were analyzed. Seventy-five TS cases with the age 7.9±2.9 years and the bone age 6.8±2.8 years were recruited. In year 1: The change of height standard deviation score (ΔHtSDS) and height velocity (HV) in Group 2 were comparable to Group 3, both two groups were higher than Group 1. ΔHtSDS and HV in all GH treatment group were higher than untreated group. IGF1 increased in all treatment groups, only 4 cases had IGF1>3 SD. In year 2: ΔHtSDS and HV in Group 2 and 3 were comparable. Five cases had IGF1>3 SD. Correlation analysis for LAGH efficacy at year 1 indicated that baseline variables correlated with ΔHtSDS include: GH dose, CA (chronological age), and bone age (BA). The HV was positively correlated with baseline GH dose, HtSDS, IGF-1SDS and negatively correlated with baseline CA, BA, and BMI. No GH-related serious adverse effects were observed. The high-dose LAGH treatment in TS patients is effective and safe as daily GH for 2 years. The favorable prognosis factors include sufficient GH dose and early treatment. IGF1 monitoring and weight control are important.

Key words

growth hormone - Turner syndrome - real world study - long acting growth hormone - IGF-1 - pituitary

Volltext

Referenzen

References
1 Zhang F, Zhang Z. Advances in diagnosis and treatment of Turner syndrome. J China-Japan Friendship Hospital 2015; 29: 3
2 Qin M, Gong C, Liu Y. Current status and progress of diagnosis and treatment of Turner syndrome in pediatrics. Med Recapit 2021; 27: 6
3 Bryant J, Baxter L, Cave CB. et al. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database of Syst Rev. 2007
4 Khadilkar VV, Khadilkar AV, Nandy M. et al. Growth hormone in turner syndrome. Indian Pediatr 2006; 43: 236-240
5 Takeda A, Cooper K, Bird A. et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-209 iii–iv
6 Li P, Cheng F, Xiu L. Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis. Endocr Connect 2018; 7: 573-583
7 Al Shaikh A, Daftardar H, Alghamdi AA. et al. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center. Acta Biomed 2020; 91: 29-40
8 Luo X, Hou L, Liang L. et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol 2017; 177: 195-205
9 Sävendahl L, Battelino T, Brod M. et al. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab 2020; 105: e1847-e1861
10 Papathanasiou T, Agersø H, Damholt BB. et al. Population pharmacokinetics and pharmacodynamics of once-daily growth hormone norditropin in children and adults. Clin Pharmacokinet 2021; 60: 1217-1226
11 Shukur HH, Hussain-Alkhateeb L, Farholt S. et al. Effects of growth hormone treatment on sleep-related parameters in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2021; 106: e3634-e3643
12 Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab 2020; 105: e2121-e2133
13 Handler MZ, Derrick KM, Lutz RE. et al. Prevalence of pilomatricoma in Turner syndrome: findings from a multicenter study. JAMA Dermatol 2013; 149: 559-564
14 Bolar K, Hoffman AR, Maneatis T. et al. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab 2008; 93: 344-351
15 Bell J, Parker KL, Swinford RD. et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95: 167-177
16 Swerdlow AJ, Cooke R, Albertsson-Wikland K. et al. Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr 2015; 84: 172-183
17 Stevens A, Clayton P, Tatò L. et al. Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome. Pharmacogenomics J 2014; 14: 54-62
18 Anonym. Clinical practice guidelines for the care of girls and women with Turner syndrome. Pediatrics 2017; 140: e20172626
19 Cleemann Wang A, Hagen CP, Nedaeifard L. et al. Growth and adult height in girls with Turner syndrome following IGF-1 titrated growth hormone treatment. J Clin Endocrinol Metab 2020; 105: dgaa274
20 Yaxin z, Hui L, Chengye L. Study on body proportions of 0-18 years old children and adolescents in China. Chin J Evidence-Based Pediatric 2010; 5: 349-354
21 Neuhauser E. Radiographic atlas of skeletal development of the knee: a standard of reference. J Am Med Assoc 1955; 159: 825-825
22 Hughes IP, Choong CS, Harris M. et al. Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response. Clin Endocrinol (Oxf) 2011; 74: 473-480
23 Polak M, Konrad D, Tønnes Pedersen B. et al. Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet international outcome study. J Pediatr Endocrinol Metab 2018; 31: 521-532
24 Luo X, Hou L, Liang L. et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol 2017; 177: 195-205
25 Sun C, Lu B, Liu Y. et al. Reduced effectiveness and comparable safety in biweekly vs. weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency: a phase IV non-inferiority threshold targeted trial. Front Endocrinol (Lausanne) 2021; 12: 779365
26 Cutfield WS, Wilton P, Bennmarker H. et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355: 610-613
27 Linglart A, Cabrol S, Berlier P. et al. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol 2011; 164: 891-897
28 Quigley CA, Crowe BJ, Anglin DG. et al. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 2002; 87: 2033-2041

Zusatzmaterial

Supplementary Material